Applies to the following strengths: 17.2%; 30%; 60%; 66.8%; 43%
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Computed Tomography
Urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography
Contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography
Computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.
Retrograde cystography and cystourethrography
Renal Dose Adjustments
Advanced Renal Disease: Iodinated contrast media should be used with caution, and only when the needed, since excretion of the medium may be impaired.
Liver Dose Adjustments
Data not available
US BOXED WARNING:
NOT FOR INTRATHECAL USE:
Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to ensure that this drug product is not administered intrathecally.
The product CYSTO-CONRAY II- iothalamate meglumine injection is not approved for intravascular administration.
Consult WARNINGS section for additional precautions.
Data not available
More about iothalamate
- Side effects
- Drug interactions
- During pregnancy or Breastfeeding
- Drug class: ionic iodinated contrast media
- Latest FDA Alerts (2)
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.